TY - JOUR
T1 - Clinical characteristics and outcomes of colorectal cancer in the colocare study
T2 - Differences by age of onset
AU - Himbert, Caroline
AU - Figueiredo, Jane C.
AU - Shibata, David
AU - Ose, Jennifer
AU - Lin, Tengda
AU - Huang, Lyen C.
AU - Peoples, Anita R.
AU - Scaife, Courtney L.
AU - Pickron, Bartley
AU - Lambert, Laura
AU - Cohan, Jessica N.
AU - Bronner, Mary
AU - Felder, Seth
AU - Sanchez, Julian
AU - Dessureault, Sophie
AU - Coppola, Domenico
AU - Hoffman, David M.
AU - Nasseri, Yosef F.
AU - Decker, Robert W.
AU - Zaghiyan, Karen
AU - Murrell, Zuri A.
AU - Hendifar, Andrew
AU - Gong, Jun
AU - Firoozmand, Eiman
AU - Gangi, Alexandra
AU - Moore, Beth A.
AU - Cologne, Kyle G.
AU - El-Masry, Maryliza S.
AU - Hinkle, Nathan
AU - Monroe, Justin
AU - Mutch, Matthew
AU - Bernadt, Cory
AU - Chatterjee, Deyali
AU - Sinanan, Mika
AU - Cohen, Stacey A.
AU - Wallin, Ulrike
AU - Grady, William M.
AU - Lampe, Paul D.
AU - Reddi, Deepti
AU - Krane, Mukta
AU - Fichera, Alessandro
AU - Moonka, Ravi
AU - Herpel, Esther
AU - Schirmacher, Peter
AU - Kloor, Matthias
AU - von Knebel-Doeberitz, Magnus
AU - Nattenmueller, Johanna
AU - Kauczor, Hans Ulrich
AU - Swanson, Eric
AU - Jedrzkiewicz, Jolanta
AU - Schmit, Stephanie L.
AU - Gigic, Biljana
AU - Ulrich, Alexis B.
AU - Toriola, Adetunji T.
AU - Siegel, Erin M.
AU - Li, Christopher I.
AU - Ulrich, Cornelia M.
AU - Hardikar, Sheetal
N1 - Funding Information:
Funding: Hardikar, Ulrich, Ose, Siegel, Toriola, Colditz, Li, Figueiredo are supported by U01206110. Hardikar is funded by K07 222060. Ulrich and Ose, and C. Himbert are funded by the Huntsman Cancer Foundation and R01 CA189184, R01 CA207371. Ulrich is also funded by P30 CA042014. C.Himbert is funded by R01 CA211705 and the Stiftung LebensBlicke. Gigic is funded by the Lackas Foundation, the ERA-NET on Translational Cancer Research (TRANSCAN) project 01KT1503, R01 CA189184, and the Stiftung Lebensblicke. Dr. Grady is funded by the Fred Hutchinson Cancer Research Center, the Seattle Translational Tumor Research Program, the Cottrell Family, and P30CA015704, U01CA152756, R01CA194663, and R01CA220004. Dr. Siegel is funded by the Florida Department of Health Bankhead Coley New Investigator Award (09BN-13) and R01 CA189184, R01 CA207371. ColoCare Moffitt has been supported in part by P30 CA076292. Toriola and Colditz are also supported by P30 CA091842.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Early-onset colorectal cancer has been on the rise in Western populations. Here, we compare patient characteristics between those with early-(<50 years) vs. late-onset (≥50 years) disease in a large multinational cohort of colorectal cancer patients (n = 2193). We calculated descriptive statistics and assessed associations of clinicodemographic factors with age of onset using mutually-adjusted logistic regression models. Patients were on average 60 years old, with BMI of 29 kg/m2, 52% colon cancers, 21% early-onset, and presented with stage II or III (60%) disease. Early-onset patients presented with more advanced disease (stages III–IV: 63% vs. 51%, respectively), and received more neo and adjuvant treatment compared to late-onset patients, after controlling for stage (odds ratio (OR) (95% confidence interval (CI)) = 2.30 (1.82–3.83) and 2.00 (1.43–2.81), respectively). Early-onset rectal cancer patients across all stages more commonly received neoadjuvant treatment, even when not indicated as the standard of care, e.g., during stage I disease. The odds of early-onset disease were higher among never smokers and lower among overweight patients (1.55 (1.21–1.98) and 0.56 (0.41–0.76), respectively). Patients with early-onset colorectal cancer were more likely to be diagnosed with advanced stage disease, to have received systemic treatments regardless of stage at diagnosis, and were less likely to be ever smokers or overweight.
AB - Early-onset colorectal cancer has been on the rise in Western populations. Here, we compare patient characteristics between those with early-(<50 years) vs. late-onset (≥50 years) disease in a large multinational cohort of colorectal cancer patients (n = 2193). We calculated descriptive statistics and assessed associations of clinicodemographic factors with age of onset using mutually-adjusted logistic regression models. Patients were on average 60 years old, with BMI of 29 kg/m2, 52% colon cancers, 21% early-onset, and presented with stage II or III (60%) disease. Early-onset patients presented with more advanced disease (stages III–IV: 63% vs. 51%, respectively), and received more neo and adjuvant treatment compared to late-onset patients, after controlling for stage (odds ratio (OR) (95% confidence interval (CI)) = 2.30 (1.82–3.83) and 2.00 (1.43–2.81), respectively). Early-onset rectal cancer patients across all stages more commonly received neoadjuvant treatment, even when not indicated as the standard of care, e.g., during stage I disease. The odds of early-onset disease were higher among never smokers and lower among overweight patients (1.55 (1.21–1.98) and 0.56 (0.41–0.76), respectively). Patients with early-onset colorectal cancer were more likely to be diagnosed with advanced stage disease, to have received systemic treatments regardless of stage at diagnosis, and were less likely to be ever smokers or overweight.
KW - Cohort
KW - Colorectal cancer
KW - Early onset
KW - Epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85111263026&partnerID=8YFLogxK
U2 - 10.3390/cancers13153817
DO - 10.3390/cancers13153817
M3 - Article
C2 - 34359718
AN - SCOPUS:85111263026
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 15
M1 - 3817
ER -